242 related articles for article (PubMed ID: 36612102)
1. Merkel Cell Carcinoma-Update on Diagnosis, Management and Future Perspectives.
Zaggana E; Konstantinou MP; Krasagakis GH; de Bree E; Kalpakis K; Mavroudis D; Krasagakis K
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612102
[TBL] [Abstract][Full Text] [Related]
2. Merkel Cell Carcinoma: An Update and Immunotherapy.
Uchi H
Front Oncol; 2018; 8():48. PubMed ID: 29560342
[TBL] [Abstract][Full Text] [Related]
3. Current and preclinical treatment options for Merkel cell carcinoma.
Celikdemir B; Houben R; Kervarrec T; Samimi M; Schrama D
Expert Opin Biol Ther; 2023; 23(10):1015-1034. PubMed ID: 37691397
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
Spassova I; Ugurel S; Kubat L; Zimmer L; Terheyden P; Mohr A; Björn Andtback H; Villabona L; Leiter U; Eigentler T; Loquai C; Hassel JC; Gambichler T; Haferkamp S; Mohr P; Pfoehler C; Heinzerling L; Gutzmer R; Utikal JS; Horny K; Schildhaus HU; Habermann D; Hoffmann D; Schadendorf D; Becker JC
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074902
[TBL] [Abstract][Full Text] [Related]
5. Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.
Schadendorf D; Nghiem P; Bhatia S; Hauschild A; Saiag P; Mahnke L; Hariharan S; Kaufman HL
Oncoimmunology; 2017; 6(10):e1338237. PubMed ID: 29123950
[TBL] [Abstract][Full Text] [Related]
6. Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications.
Walsh NM; Castonguay MC; Carter MD; Pasternak S; Ly TY; Doucette S; Hanly JG; Saggini A; Cerroni L
Am J Dermatopathol; 2019 Nov; 41(11):819-825. PubMed ID: 31634167
[TBL] [Abstract][Full Text] [Related]
7. Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma.
Hanna GJ; Kacew AJ; Tanguturi AR; Grote HJ; Vergara V; Brunkhorst B; Rabinowits G; Thakuria M; LeBoeuf NR; Ihling C; DeCaprio JA; Lorch JH
Front Med (Lausanne); 2020; 7():198. PubMed ID: 32582722
[No Abstract] [Full Text] [Related]
8. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
Gehrcken L; Sauerer T; Schaft N; Dörrie J
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
[TBL] [Abstract][Full Text] [Related]
9. An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy.
Fojnica A; Ljuca K; Akhtar S; Gatalica Z; Vranic S
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894451
[TBL] [Abstract][Full Text] [Related]
10. [Immune checkpoint inhibition in Merkel cell carcinoma].
Terheyden P; Mohr A; Langan EA
Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
[TBL] [Abstract][Full Text] [Related]
11. Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6-7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A.
Guadagni S; Farina AR; Cappabianca LA; Sebastiano M; Maccarone R; Zelli V; Clementi M; Chiominto A; Bruera G; Ricevuto E; Fiorentini G; Sarti D; Mackay AR
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153070
[TBL] [Abstract][Full Text] [Related]
12. Combining DNA Damage Induction with BCL-2 Inhibition to Enhance Merkel Cell Carcinoma Cytotoxicity.
Liu W; Krump NA; Herlyn M; You J
Biology (Basel); 2020 Feb; 9(2):. PubMed ID: 32093022
[TBL] [Abstract][Full Text] [Related]
13. Merkel Cell Polyomavirus Small T Antigen Drives Cell Motility via Rho-GTPase-Induced Filopodium Formation.
Stakaitytė G; Nwogu N; Dobson SJ; Knight LM; Wasson CW; Salguero FJ; Blackbourn DJ; Blair GE; Mankouri J; Macdonald A; Whitehouse A
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093086
[TBL] [Abstract][Full Text] [Related]
14. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers.
Afanasiev OK; Yelistratova L; Miller N; Nagase K; Paulson K; Iyer JG; Ibrani D; Koelle DM; Nghiem P
Clin Cancer Res; 2013 Oct; 19(19):5351-60. PubMed ID: 23922299
[TBL] [Abstract][Full Text] [Related]
15. Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma.
von der Grün J; Winkelmann R; Meissner M; Wieland U; Silling S; Martin D; Fokas E; Rödel C; Rödel F; Balermpas P
Front Oncol; 2019; 9():20. PubMed ID: 30733932
[No Abstract] [Full Text] [Related]
16. Merkel Cell Carcinoma in the HIV-1/AIDS Patient.
Goldstein RH; DeCaprio JA
Cancer Treat Res; 2019; 177():211-229. PubMed ID: 30523626
[TBL] [Abstract][Full Text] [Related]
17. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.
Mitteldorf C; Berisha A; Tronnier M; Pfaltz MC; Kempf W
J Cutan Pathol; 2017 Sep; 44(9):740-746. PubMed ID: 28569410
[TBL] [Abstract][Full Text] [Related]
18. Merkel cell carcinoma update: the case for two tumours.
Nirenberg A; Steinman H; Dixon J; Dixon A
J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1425-1431. PubMed ID: 31855292
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
Barkdull S; Brownell I
Cancer Biol Ther; 2017 Dec; 18(12):937-939. PubMed ID: 29172995
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
